期刊文献+

抗EGFR治疗与结直肠癌K-ras基因突变状态的研究进展 被引量:1

原文传递
导出
摘要 结直肠癌是最常见的消化道肿瘤之一,严重威胁着人类的健康。目前全球结直肠癌新发病例占全部癌症的9.4%,发病率排位男性居第4位,女性居第3位,现有的结直肠癌患者数量仅次于乳腺癌^[1]。结直肠癌在全球的发病率和死亡率仍呈上升趋势,2007年全球结直肠癌新病例接近120万,死亡63万,分别比2000年增加27%和28%,
出处 《中华普通外科学文献(电子版)》 2011年第3期56-58,共3页 Chinese Archives of General Surgery(Electronic Edition)
  • 相关文献

参考文献27

  • 1Parkin DM,Bray F,Ferlay J,et al.Global cancer statistics,2002.CA Cancer J Clin,2005,55(2):74-108.
  • 2American Cancer Society.Global Cancer Facts & Figures 2007.Atlanta,GA:American Cancer Society,2007:12-13.
  • 3Jemal A,Siegel R,Ward E,et al.Cancer statistics,2009.CA Cancer J Clin,2009,59(4):225-249.
  • 4杨玲,李连弟,陈育德,D.M.Parkin.中国2000年及2005年恶性肿瘤发病死亡的估计与预测[J].中国卫生统计,2005,22(4):218-221. 被引量:336
  • 5De GA,Figer A,Seymour M,et al.Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.J Clin Oncol,2000,18(16):2938-2947.
  • 6O'Connell JB,Maggard MA,Ko CY.Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging.J Natl Cancer Inst,2004,96(19):1420-1425.
  • 7Ochenduszko SL,Krzemieniecki K.Targeted therapy in advanced colorectal cancer:more data,more questions.Anticancer Drugs,2010,21(8):737-748.
  • 8Jonker DJ,O'Callaghan CJ,Karapetis CS,et al.Cetuximab for the treatment of colorectal cancer.N Engl J Med,2007,357(20):2040-2048.
  • 9Van Cutsem E,Peeters M,Siena S,et al.Open-label phase Ⅲ trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.J Clin Oncol,2007,25(13):1658-1664.
  • 10Saltz LB,Meropol NJ,Loehrer PJ Sr,et al.Phase Ⅱ trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.J Clin Oncol,2004,22(7):1201-1208.

二级参考文献17

  • 1李连弟,鲁凤珠.1990—1992年中国恶性肿瘤死亡流行分布情况分析[J].中华肿瘤杂志,1996,18(6):403-407. 被引量:227
  • 2李连弟,鲁凤珠,张思维,牧人,孙秀娣,皇甫小梅,孙杰,周有尚,欧阳宁慧,饶克勤,陈育德,孙爱明,薛志福,夏毅.中国恶性肿瘤死亡率20年变化趋势和近期预测分析[J].中华肿瘤杂志,1997,19(1):3-9. 被引量:869
  • 3Ferlay J, Bray F, Pisani P, et al. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide, Version 2.0. IARC Cancer Base No 5. Lyon, IARCPress, 2004.
  • 4Yang L, Parkin DM, Li LD, et al. A comparison of the sources ofeancer mortality in China. Cancer Causes Conhol, 2004, 15(7) : 1581-7.
  • 5International Agency for Research on Cancer. Cancer Mortality Database. http://www-deodb, iarc. fr/who/menu, hun.
  • 6Parkin DM, Whelan SL, Ferlay J, et al. Cancer in Five Continents Vol.VIII. IARC Scientific Publication No. 155, Lyon, FraQce: IARC-Press; 2002.
  • 7United Nations, Population Division (2003) World Population Prospects: The 2002 Revision. Population Database. http://esa, un.org/unpp.
  • 8Yang L, Parkin DM, Li LD, et al. Time Trends in Cancer mortality in China: 1987-1999. International J Cancer, 2003,106(5) :771-83).
  • 9Yang L, Parkin DM, Li LD, et al. Estimation and projection of the national profile of cancer mortality in China: 1991 - 2005. British Journal of Cancer, 2004, 90:2157-2166.
  • 10Yang L, Parkin DM, Ferlay J, et al. Estimates of cancer in cidenee in China for 2000 and projection for 2005. Cancer Epidemiology, Biomarkers & Prevention. 2005, 14( 1 ) : 243-250.

共引文献335

同被引文献17

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部